RS64738B9 - Kombinovana terapija protiv kancera sa antagonistom iap i anti pd-1 molekulom - Google Patents

Kombinovana terapija protiv kancera sa antagonistom iap i anti pd-1 molekulom

Info

Publication number
RS64738B9
RS64738B9 RS20230994A RSP20230994A RS64738B9 RS 64738 B9 RS64738 B9 RS 64738B9 RS 20230994 A RS20230994 A RS 20230994A RS P20230994 A RSP20230994 A RS P20230994A RS 64738 B9 RS64738 B9 RS 64738B9
Authority
RS
Serbia
Prior art keywords
molecule
cancer therapy
combination
iap antagonist
anti cancer
Prior art date
Application number
RS20230994A
Other languages
English (en)
Inventor
Grégoire Vuagniaux
Norbert Wiedemann
Bruno Gavillet
Altman Sergio Adrian Szyldergemajn
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of RS64738B1 publication Critical patent/RS64738B1/sr
Publication of RS64738B9 publication Critical patent/RS64738B9/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20230994A 2017-12-21 2018-12-21 Kombinovana terapija protiv kancera sa antagonistom iap i anti pd-1 molekulom RS64738B9 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2017/001595 WO2019122941A1 (en) 2017-12-21 2017-12-21 Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
PCT/EP2018/086606 WO2019122337A1 (en) 2017-12-21 2018-12-21 Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
EP18829861.6A EP3728313B9 (en) 2017-12-21 2018-12-21 Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule

Publications (2)

Publication Number Publication Date
RS64738B1 RS64738B1 (sr) 2023-11-30
RS64738B9 true RS64738B9 (sr) 2023-12-29

Family

ID=61022374

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230994A RS64738B9 (sr) 2017-12-21 2018-12-21 Kombinovana terapija protiv kancera sa antagonistom iap i anti pd-1 molekulom

Country Status (23)

Country Link
US (1) US20210093645A1 (sr)
EP (2) EP4285927A3 (sr)
JP (2) JP7438947B2 (sr)
KR (1) KR20200103737A (sr)
CN (1) CN111542542A (sr)
AU (1) AU2018386626A1 (sr)
BR (1) BR112020012250A2 (sr)
CA (1) CA3085389A1 (sr)
DK (1) DK3728313T3 (sr)
EA (1) EA202091539A1 (sr)
ES (1) ES2960585T3 (sr)
FI (1) FI3728313T3 (sr)
HR (1) HRP20231358T1 (sr)
HU (1) HUE063487T2 (sr)
IL (1) IL275389A (sr)
LT (1) LT3728313T (sr)
MX (1) MX2020006534A (sr)
PL (1) PL3728313T3 (sr)
PT (1) PT3728313T (sr)
RS (1) RS64738B9 (sr)
SG (1) SG11202005759YA (sr)
SI (1) SI3728313T1 (sr)
WO (2) WO2019122941A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120586A1 (en) 2018-11-28 2020-06-04 Histosonics, Inc. Histotripsy systems and methods
WO2021110011A1 (en) * 2019-12-02 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
EP4096782A4 (en) * 2020-01-28 2024-02-14 Univ Michigan Regents SYSTEMS AND METHODS FOR IMMUNOSENSITIZATION BY HISTOTRIPSY
CN111948395A (zh) * 2020-08-19 2020-11-17 复旦大学附属金山医院 用于诊断三阴性乳腺癌免疫调节亚型的四联标志物及其应用
CN112194723B (zh) * 2020-09-25 2021-09-21 广州百吉生物制药有限公司 一种免疫细胞在治疗癌症中应用
WO2022179490A1 (en) * 2021-02-23 2022-09-01 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical compositions and preparation methods thereof
AU2022280511A1 (en) 2021-05-28 2023-12-14 Nippon Kayaku Kabushiki Kaisha Combined use of ubenimex and immune checkpoint inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010224A2 (pt) * 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
WO2016049677A1 (en) * 2014-10-03 2016-04-07 The Walter And Eliza Hall Institute Of Medical Research Method of treating cancer
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
AU2016369537B2 (en) * 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
WO2017143449A1 (en) 2016-02-24 2017-08-31 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2020148447A1 (en) * 2019-01-17 2020-07-23 Debiopharm International S.A. Combination product for the treatment of cancer

Also Published As

Publication number Publication date
HUE063487T2 (hu) 2024-01-28
DK3728313T3 (da) 2023-10-30
HRP20231358T1 (hr) 2024-02-16
ES2960585T3 (es) 2024-03-05
PL3728313T3 (pl) 2024-01-22
EP4285927A2 (en) 2023-12-06
IL275389A (en) 2020-07-30
AU2018386626A1 (en) 2020-07-02
EP3728313B1 (en) 2023-08-02
EP3728313B9 (en) 2023-10-25
WO2019122941A1 (en) 2019-06-27
BR112020012250A2 (pt) 2020-11-24
EA202091539A1 (ru) 2020-09-17
SG11202005759YA (en) 2020-07-29
WO2019122337A1 (en) 2019-06-27
LT3728313T (lt) 2023-11-10
FI3728313T3 (fi) 2023-11-01
CA3085389A1 (en) 2019-06-27
MX2020006534A (es) 2020-12-09
CN111542542A (zh) 2020-08-14
EP4285927A3 (en) 2024-03-06
JP2021506781A (ja) 2021-02-22
PT3728313T (pt) 2023-10-23
JP2024059699A (ja) 2024-05-01
US20210093645A1 (en) 2021-04-01
RS64738B1 (sr) 2023-11-30
EP3728313A1 (en) 2020-10-28
SI3728313T1 (sl) 2023-12-29
KR20200103737A (ko) 2020-09-02
JP7438947B2 (ja) 2024-02-27

Similar Documents

Publication Publication Date Title
IL275389A (en) Combined anti-cancer therapy with an IAP antagonist and an anti-PD-1 molecule
IL262892A (en) Anti-pd-1 and anti-lag3 antibodies for cancer therapy
HK1247848A1 (zh) 抗pd-1和抗m-csf抗體在治療癌症中的聯合應用
IL271946A (en) Combination for cancer treatment
EP3368656A4 (en) TARGETED CANCER THERAPY
PT3423087T (pt) Terapia de cpombinação contra o cancro
EP3411505A4 (en) DETECTION AND DIAGNOSIS OF CANCER EVOLUTION
IL265786A (en) Materials and methods for increasing radiotherapy against cancer
EP3713585A4 (en) MSC-EXPRESSED IMMUNE MODULATORS IN COMBINATION WITH CAR-T FOR CANCER THERAPY
IL271326A (en) Compositions and methods for enhancing radiotherapy in cancer
EP3174985A4 (en) An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
EP3331542A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER ASSOCIATED WITH ETBR ACTIVATION
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3256115A4 (en) COMBINATION CANCER THERAPY
EP3532638A4 (en) TARGETING MICROARN-101-3 P IN CARCINOTHERAPY
EP3380468B8 (en) Bis-pyridazine compounds and their use in treating cancer
EP3675891A4 (en) ANTI-CANCER POLYTHERAPY
EP3528834A4 (en) TREATMENT OF CANCER USING A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 ANTAGONIST
EP3548070A4 (en) METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPY
PL3189200T3 (pl) Brama przesuwna w przedniej części i samonośna w tylnej części
EP3515470A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING SKIN INFLAMMATION AND FOR DETERMINING THE SENSITIVITY TO CANCER
GB201818198D0 (en) Delivery vehicle configurations and corresponding methods
EP3334471C0 (en) IMPROVED CANCER TREATMENT WITH DOXORUBICINE
IL274866A (en) Preparations and methods for the treatment of cancer
PT3458478T (pt) Anticorpos anti pd-1 e anti-lag3 para tratamento de cancro